USA flag logo/image

An Official Website of the United States Government

Targeted Molecular Radiotherapy for Rheumatoid Arthritis

Award Information

Agency:
Department of Energy
Branch:
N/A
Award ID:
89887
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
85445
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
SIBTECH, INC.
115A Commerce Drive Brookfield, CT 06804-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Targeted Molecular Radiotherapy for Rheumatoid Arthritis
Agency: DOE
Contract: DE-FG02-08ER85179
Award Amount: $99,909.00
 

Abstract:

The progression of rheumatoid arthritis (RA), specifically, the growth of the bone-destroying pannus in RA joints, depends on the formation of new blood vessels, whose growth is mediated primarily by vascular endothelial growth factor (VEGF) and its cognate receptors. VEGF and its receptors are highly expressed at the RA joints and therapeutic strategies that target RA-associated VEGF signaling are under intense pre-clinical and clinical testing. However, the fundamental shortcoming of these strategies is that they target only endothelial cells and thereby provide, at best, only cytostatic effects that would require continuous therapy. Thus, there is an unmet need for more effective targeted therapies. This project will develop a radiopharmaceutical that will destroy endothelial and other pannus cells involved in pathology of RA joints. The approach is based on the hypothesis that therapeutically significant doses of Lu-177 radiopharmaceutic can be selectively delivered to RA joints by targeting overexpressed VEGF receptors in RA angiogenic vasculature. This approach is designed to destroy both angiogenic vasculature and destructive inflammatory cells within the pannus of a diseased joint. In Phase I, the hypothesis will be tested in a mouse model of collagen-induced immune mediated arthritis, with the goal of establishing a regimen for the delivery of a safe but therapeutically significant dose of Lu-177 to RA joints. Commercial Applications and other Benefits as described by the awardee: The targeted radiopharmaceutical should reduce the disease burden for the two percent of the population that already suffers from rheumatoid arthritis, and potentially for many more among rapidly aging baby boomers.

Principal Investigator:

Joseph M. Backer
Dr.
2037755677
jbacker@sibtech.com

Business Contact:

Joseph Backer
Dr.
2037755677
jbacker@sibtech.com
Small Business Information at Submission:

Sibtech, Inc.
115A Commece Drive Brookfield, CT 06804

EIN/Tax ID: 133992292
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No